Effective Wednesday, November 13, 2019, the new Mycoplasma genitalium (mgen) assay is now available using the Aptima target nucleic acid amplification test (NAAT) for the qualitative detection of ribosomal RNA (rRNA) from Mycoplasma genitalium to aid in the diagnosis of M. genitalium urogenital infections in male and female patients.
Browsing Category
Advanced Technology Laboratory
Advanced Technology Laboratory, Cytogenetics, General Information, Test Spotlight
Test Enhancement Microarray (aCGH) Analysis
Effective May 20, 2019, Spectrum Health Regional Laboratory Cytogenetics Department is pleased to announce the launch of a new microarray platform AffymetrixTM Cytoscan® HD. The Affymetrix Cytoscan HD is designed for the accurate and comprehensive analysis of chromosomal variants in the human genome.
Advanced Technology Laboratory, Cytogenetics, Flow Cytometry, General Information, Molecular Diagnostics
Advanced Technology Laboratory plays an important role in Oncology
Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.
The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”
“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”
“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”
-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant
Advanced Technology Laboratory, Cytogenetics, Molecular Diagnostics, Test Spotlight
Lung Cancer Mutation Analysis Panel provides targeted treatments for patients
The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).